Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; 25 of the 72 sources its claims cite were checked for support.
Abstract
Cellular senescence suppresses cancer by arresting cell proliferation, essentially permanently, in response to oncogenic stimuli, including genotoxic stress. We modified the use of antibody arrays to provide a quantitative assessment of factors secreted by senescent cells. We show that human cells induced to senesce by genotoxic stress secrete myriad factors associated with inflammation and malignancy. This senescence-associated secretory phenotype (SASP) developed slowly over several days and only after DNA damage of sufficient magnitude to induce senescence. Remarkably similar SASPs developed in normal fibroblasts, normal epithelial cells, and epithelial tumor cells after genotoxic stress in culture, and in epithelial tumor cells in vivo after treatment of prostate cancer patients with DNA-damaging chemotherapy. In cultured premalignant epithelial cells, SASPs induced an epithelial-mesenchyme transition and invasiveness, hallmarks of malignancy, by a paracrine mechanism that depended largely on the SASP factors interleukin (IL)-6 and IL-8. Strikingly, two manipulations markedly amplified, and accelerated development of, the SASPs: oncogenic RAS expression, which causes genotoxic stress and senescence in normal cells, and functional loss of the p53 tumor suppressor protein. Both loss of p53 and gain of oncogenic RAS also exacerbated the promalignant paracrine activities of the SASPs. Our findings define a central feature of genotoxic stress-induced senescence. Moreover, they suggest a cell-nonautonomous mechanism by which p53 can restrain, and oncogenic RAS can promote, the development of age-related cancer by altering the tissue microenvironment.
Overview
CoChat Summary
TL;DR
Senescent human fibroblasts and epithelial cells develop a complex senescence-associated secretory phenotype (SASP) that can promote malignant phenotypes in neighboring cells, including epithelial–mesenchymal transition (EMT) and invasion. Oncogenic RAS and loss of p53 amplify and accelerate this SASP, suggesting p53 acts as a cell-nonautonomous tumor suppressor by restraining protumorigenic secreted factors.
Key findings
- Of 120 proteins assayed, 41 were significantly oversecreted by senescent cells compared with presenescent cells, while 79 showed no significant difference; the SASP included inflammatory cytokines/chemokines, growth factors, shed surface molecules, and survival factors.
- The SASP was conserved across cell types: normal fibroblasts and normal prostate epithelial cells overlapped significantly (p ≈ 10⁻³; r = 0.53; >66% overlap), and 24 proteins were shared between all fibroblast and all epithelial SASPs (p ≈ 10⁻⁵).
- SASP induction required genotoxic stress sufficient to cause senescence: 10 Gy X-irradiation induced a SASP, whereas 0.5 Gy did not; the SASP developed slowly, requiring 4–7 d after irradiation.
- Oncogenic RAS induced an amplified SASP: correlations with REP/XRA SASPs were 0.75 for WI-38/IMR-90 and 0.84 for HCA-2 fibroblasts; nine proteins were significantly more secreted in SEN(RAS) versus SEN(REP;XRA) across all fibroblasts, plus five RAS-unique proteins.
- p53 loss was not required to initiate or maintain a SASP, but it amplified it: a subset of SASP proteins was secreted at 5- to 30-fold higher levels after p53 inactivation, and combined p53 loss plus oncogenic RAS produced the most amplified SASP, with accelerated development within 2–4 d.
- SASP factors induced EMT and invasion in nonaggressive breast cancer cells; IL-6 and IL-8 blocking antibodies reduced SEN CM–stimulated invasion.
- In human prostate cancer biopsies after mitoxantrone chemotherapy, tumors showed higher p16INK4a and p21 mRNAs, lower cyclin A, MCM-3, and PCNA mRNAs, and higher mRNAs for IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β, while IL-2 mRNA did not significantly change.
Methods
- Human fibroblast strains (WI-38, IMR-90, BJ, HCA2, hBF184), normal prostate epithelial cells (PrECs), and prostate tumor lines (BPH1, RWPE1, PC3) were induced to senesce by replicative exhaustion (REP), 10 Gy X-irradiation (XRA), oncogenic RAS, or mitoxantrone (MIT); p53 was inactivated using GSE22 or shRNA.
- Conditioned media were analyzed with modified antibody arrays detecting 120 proteins, using ³⁵S-streptavidin detection for improved dynamic range; findings were validated by ELISA, immunostaining, invasion assays, and RT-PCR.
- Human prostate cancer biopsies were obtained before and after MIT chemotherapy; approximately 1,000 tumor epithelial cells were laser-captured per sample, and mRNA was quantified by RT-PCR. Statistical analyses used Pearson correlation, two-tailed Student t-test, and hypergeometric distribution for SASP overlap.
Limitations
- The paper does not include a formal limitations section.
- Evident from the text: the in vivo human SASP evidence relies on mRNA from laser-captured tumor cells rather than direct measurement of secreted proteins, with approximately 1,000 cells captured per sample.
- Evident from the text: many mechanistic conclusions come from cultured cells, and the SASP is described as not a fixed phenotype, with quantitative and qualitative differences among cell strains, tissues, and donors.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Chemotherapy-Induced SASP in Culture and In Vivo (A) Overall correlation between XRA and mitoxantrone (MIT)-induced SASPs for all three prostate epithelial cancer cell lines (BPH-1, RWPE-1, and PC-3). Correlations for the individual cell lines are given in the table to the right. The senescence inducer (XRA or MIT) is given in parentheses. (B–E) Human tumor cells were isolated from biopsies obtained from the same patient before MIT chemotherapy and from prostate tissue following prostatectomy after MIT chemotherapy. Laser captured cells were analyzed by quantitative RT-PCR for the mRNAs encoding the indicated proteins, as described in Materials and Methods and Text S1. The results are displayed on a log10 scale indicating the values before (horizontal or x-axis) compared to after (vertical or y-axis) chemotherapy (top left panel in [B]). Each black dot in (B, C, and D) represents the results obtained from a single patient. The average values for all patients before versus after chemotherapy are indicated by a red dot (B–D); these values are also represented as a heat map in (E). (B) Values for mRNAs encoding proteins associated with senescence (p16 and p21) and proliferation (cyclin A, MCM-3, and PCNA). (C) Values for mRNAs encoding SASP-associated proteins (IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β). (D) Value for an mRNA encoding a non-SASP–associated protein (IL-2). (E) Averages for the values shown in (B–D). Overall p-values, determined by the Student t-test, and number of paired samples (or patients) analyzed for each mRNA are given to the right of the heat map. Signals higher than the prechemotherapy baseline are shown in red; signals below baseline are displayed in green.](https://figures.cochat.ai/paper-figures/92013b1ef9b3492d8c26b76b40577c28/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-3.jpg)


![Figure 6 p53 Restrains the SASP (A) CM containing factors secreted by the indicted cells were analyzed by antibody arrays and displayed, using PRE CM as the baseline. We pooled data from cells of the same genotype (p53 wild type or p53 deficient) under the same culture conditions. SEN indicates pooled data from cells originating from the same tissue (WI-38, IMR-90 from embryonic lung; and HCA-2, BJ from neonatal foreskin) and induced to senesce by REP or XRA. Pooling and averaging of highly correlated samples was performed as described for Figure 5, and details of the data processing are provided in Datasets S13–S16. The top four rows are the same top four rows in Figure 5A and are included to serve as a visual reference. The senescence inducer is given in parentheses. p53 status is indicated as either wild type (wt) or deficient (d) owing to either GSE22 expression or expression of an shRNA against p53. Manipulations are indicated in sequence, separated by a greater than symbol (>). The heat map key (right) indicates the log2-fold changes. Signals higher than the baseline are shown in yellow; signals below baseline are displayed in blue. Comparison between rows is accurately illustrated in (B) and (C) in which each genetically manipulated cell type is compared to its appropriate control baseline. (B) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from SEN cells made p53 deficient by GSE22, using untreated wild-type SEN values as the baseline. Green indicates WI-38 cells made senescent by XRA, after which p53 was subsequently inactivated by expressing GSE22 using a lentivirus; these cells do not resume proliferation (“unreverted”) upon p53 inactivation (see Figure S6). Blue indicates WI-38 in which p16 was inactivated by an shRNA, induced to senesce by XRA, then infected with the GSE22-expressing lentivirus; these cells do revert (REV) after p53 inactivation. Pink indicates HCA2 cells made SEN by XRA, then infected with GSE22 lentivirus; these cells also revert after p53 inactivation. (C) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from cells made p53-deficient (by GSE22 expression), then induced to senesce by REP, XRA, or RAS. Red indicates WI-38 and IMR90 (averaged) cells expressing GSE22, then induced to senesce by XRA or REP, using cells made SEN by XRA or REP as a baseline. Gray indicates WI-38, IMR-90, and HCA2 (averaged) expressing GSE22, then made senescent by RAS, using SEN by RAS as a baseline. (D) WI-38 cells expressing GSE22 were induced to senesce by XRA and then immunostained for the SASP proteins IL-6 and IL-8, the senescence marker p16INK4a, and p53, which accumulates in the presence of GSE22. (E) Comparative graphical representation of the secretory profiles of cells made senescent by XRA or REP (dotted line), RAS (black line), p53 inactivation (GSE22) followed by XRA or REP (blue line), or p53 inactivation (GSE22) followed by RAS (red line). The increased slopes (as indicated by the arrow)indicate amplified SASPs. (F) Hierarchical cluster analysis of all the cells analyzed in (A), plus the SASP induced by RAS (see Figure 5). RAS status is indicated as either wild type (wt) or oncogenic (o) owing to expression of Ha-RASv12. (G) WI-38 cells with wild-type (wt) or inactive (GSE) p53 were irradiated or induced to express oncogenic RAS (RAS), and CM was collected 4 or 10 d later. Soluble factors were analyzed by antibody arrays and displayed as described in Figure 1D, using PRE CM as the baseline (black column on the left; see also Figure S5C for details). Signals higher than baseline are shown in yellow; signals below baseline are in blue. n/a, not applicable. (H) Log2-fold values for prostate epithelial cell SASP factors that are significantly or uniquely (as indicated by double asterisks [**]) elevated in CM from p53-deficient cancer cells (PC3, BPH1, and RWPE1) that were induced to senesce by XRA, compared to primary p53 wild-type cells (PrECs) that were induced to senesce by XRA.](https://figures.cochat.ai/paper-figures/ec6066e9173e4732bc7f9d2c5718a2dd/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-6.jpg)
![Figure 7 Biological Activities of the Amplified SASP (A) T47D and ZR75.1 cells were incubated with the indicated CM for 3 d and then analyzed for cell scattering, immunostained for the indicated proteins, and analyzed for vimentin and actin levels by western blotting. Controls for the immunofluorescence from the same individual experiment are shown in Figure 4B. The senescence inducer is given in parentheses. p53 status was either wild type or deficient (GSE). Manipulations are indicated in sequence, separated by >. (B) Epithelial cells were incubated with CM from the indicated WI-38 cells and assayed for invasion as described in Materials and Methods and Figure 3C. Double asterisks (**) indicate p < 0.02. Error bars indicate the standard deviation around the mean. (C) Epithelial cells were incubated with CM from the indicated fibroblasts and cell number was determined by cell counting, total protein, or green fluorescent protein (GFP) fluorescence using epithelial cells expressing GFP, as described in [80]. A single asterisks (*) indicates p < 0.05. Error bars indicate the standard deviation around the mean. (D) Model for the cell-nonautonomous activities of oncogenic RAS and the p53 tumor suppressor protein. Oncogenic and genotoxic stress of sufficient magnitude to cause senescence induce a SASP, whereby cells secrete inflammatory cytokines, chemokines, and growth factors that can alter the tissue microenvironment and stimulate malignant phenotypes in nearby cells. Thus, in addition to their well-known cell-autonomous effects, oncogenes can promote cancer cell-nonautonomously by inducing a SASP. Oncogenic and genotoxic stress also activate p53, which suppresses cancer by cell-autonomous mechanisms (promoting repair, or inducing apoptosis or senescence). In addition, p53 suppresses cancer by the cell-nonautonomous effects of suppressing the intensity of the SASP and its deleterious effects.](https://figures.cochat.ai/paper-figures/c8eed762510f438c8789f2db0ec751a6/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-7.jpg)
Verification
Claims the paper makes
19 Valid · 4 Not valid · 9 Not checked · 117 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lastly, in mice and humans, a senescence response to strong mitogenic signals, such as those delivered by certain oncogenes, prevents premalignant lesions from progressing to malignant cancers [ 16 – 19 ].”
What the sources say
- Not checked — no full text of the sourcecites [16] Collado, 2005, Nature source
- Partly supportedcites [17] Chen, 2005, Nature sourceExperimental — accuracy not yet measured
The Abstract reports that p53-dependent senescence restricts Pten-deficient tumorigenesis in mice, and the human-specimen passage reports senescence staining mainly in prostate hyperplasia or PIN rather than frank tumour (page numbers unavailable). The human observations do not establish that senescence prevents progression, and the experimental finding concerns Pten loss rather than strong mitogenic signals generally. (LLM, conf=0.86)
- Partly supportedcites [18] Michaloglou, 2005, Nature sourceExperimental — accuracy not yet measured
The discussion (Nature, vol. 436, 4 August 2005; page not provided) says the findings support oncogene-induced senescence as a mechanism in humans that limits progression of premalignant lesions. The paper studies human melanocytes and naevi, not mice, and describes limitation of progression rather than categorical prevention. (LLM, conf=0.88)
- Not matchedcites [19] Braig, 2005, Nature
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Consistent with this view, senescent cells increase with age in mammalian tissues [ 27 ]”
What the sources say
- Supportedcites [27] Campisi, 2005, Cell source
The “Cellular Senescence and Aging” passage (page not provided) says that cells with characteristics of senescence accumulate with age in multiple tissues from humans and rodents. This supports the claim about mammalian tissues. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescent cells acquire many changes in gene expression, mostly documented as altered mRNA abundance, including increased expression of secreted proteins [ 33 – 41 ].”
What the sources say
- Partly supportedcites [33] Zhang, 2003, Proc Natl Acad Sci U S A sourceExperimental — accuracy not yet measured
The Results report hundreds of changes in transcript abundance during senescence in human fibroblasts, supporting the claim about altered gene expression measured as mRNA. They identify up-regulated genes encoding membrane-associated proteins, but the passages in our copy do not establish increased expression of secreted proteins; membrane-associated is not the same as secreted. (LLM, conf=0.85)
- Supportedcites [34] Chang, 2002, Proc Natl Acad Sci U S A source
The Results and Discussion report many gene-expression changes in senescent HCT116 cells, measured primarily with RNA-based methods, and specifically identify increased expression of genes for secreted factors. The paper also notes parallels with senescence in normal cells. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [35] Bavik, 2006, Cancer Res source
- Not checked — no full text of the sourcecites [36] Mason, 2004, Oncogene source
- Not checked — no full text of the sourcecites [37] Wajapeyee, 2008, Cell source
- Not matchedcites [38] Kortlever, 2006, Nat Cell Biol
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [39] Parrinello, 2005, J Cell Sci source
- Supportedcites [40] Kuilman, 2008, Cell source
The Results (page not provided) report genome-wide expression analysis showing multiple gene classes upregulated during oncogene-induced senescence, including cytokine and chemokine genes. They also report increased IL-6 and IL-8 expression and secretion of IL-6 by senescent cells, supporting the claim about secreted proteins. (LLM, conf=0.91)
- Supportedcites [41] Acosta, 2008, Cell source
The Discussion (page unavailable) identifies increased production of various secreted proteins as a characteristic of senescent cells. It also reports that CXCR2 and many of its ligands are upregulated during senescence, supporting the claim about changes in expression. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Thus, oncogenes such as RAS, which are known to activate protumorigenic paracrine mechanisms during transformation [ 59 – 61 ], might also exert cell-nonautonomous protumorigenic effects through nontransformed cells during the process of inducing senescence ( Figure 7 D).”
What the sources say
- Supportedcites [59] Ancrile, 2007, Genes Dev source
The citation supports the sentence’s background clause about protumorigenic paracrine mechanisms during RAS-driven transformation. The Abstract says RAS-induced IL6 acts in a paracrine fashion to promote angiogenesis and tumor growth; the Summary likewise describes this effect in RAS-driven tumor cells. The later suggestion about senescence is the citing authors’ own inference, not a finding attributed to this source. (LLM, conf=0.92)
- Supportedcites [60] Yang, 2006, Proc Natl Acad Sci U S A source
The Discussion states that RAS signals to stromal cells through Gro-1, inducing senescence and promoting tumor growth or malignant transformation. The paper’s opening summary also reports that Gro-1-induced senescent fibroblasts promote tumor growth, supporting the proposed cell-nonautonomous effect. Page numbers are not provided in our copy. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [61] Akhurst, 2001, Trends Cell Biol source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our results showed that human tumor cells very likely undergo senescence in response to DNA damaging chemotherapy in vivo, as reported for mice [ 49 ].”
What the sources say
- Supportedcites [49] Schmitt, 2002, Cell source
The citation is attached to “as reported for mice,” not to the citing authors’ finding about human tumor cells. The cited paper’s Discussion reports chemotherapy-induced senescence in vivo in a murine lymphoma model; it does not itself establish the human finding. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
89 more claims · 3 with their cited sources checked
Create a free account to see all 149 claims and every source verdict.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 41
- Borderline: one of the tests for a substantial claim is unclear. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the effects of the senescent fibroblasts were due primarily to their secretion of matrix metalloproteinases (MMPs), which are prominent SASP components (32, 94).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Senescent cells are metabolically active and can acquire a pro-inflammatory, tissue-destructive, pro-apoptotic senescence-associated secretory phenotype (SASP) [26]”
From Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease (2019) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although it was robustly induced 7–10 days after cultured MEFs were stimulated to senesce by IR (Coppé et al., 2008)”
From An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA (2014) · cites this paper as Coppé et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SASP is primarily a property of cells that senesce owing to, or accompanied by, genomic damage or epigenomic perturbation.”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many types of cytotoxic chemotherapies are severe DNA-damaging agents that can induce senescence in both tumor cells and surrounding normal cells (31–34).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measured
80 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“We thank R. Driver for support with the array experiments, J. Gray and R. Neve for discussions, cells, and use of Cellomix; A. Huang for help with the microdissection and PCR; A. Zielinski and J. Allison for technical help; T. Beer, M. Garzotto, C. Higano, L. True, R. Vessella, and the University of Washington Medical…”
BackgroundMethodInfluentialOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“prototype [56], induce senescence in part by indirectly”
BackgroundCellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441 · cited 1×
“Several lines of evidence indicate that cellular senescence is a potent tumor-suppressive mechanism [4,9,10].”
BackgroundSelf-citationPleiotropy, natural selection, and the evolution of senescence.
Williams, G. C. (1957) · Evolution · doi:10.1111/j.1558-5646.1957.tb02911.x · Cited by 4,279 · cited 1×
“It is now recognized that aging is a consequence of the declining force of natural selection with age [26,70].”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“Moreover, human cells that bypass oncogene-induced senescence [58], as well as cells in some human premalignant lesions [73,74], show signs of a persistently activated DDR.”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“Recent findings show that tumors induced to senesce in mice gradually regress [21,22], owing perhaps to infiltration by cells of the innate immune system [22].”
BackgroundSenescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Research works printed but not linked: 80
- Hanahan, 2000, Cell, 100, 57
- Bissell, 2001, Nature Rev Cancer, 1, 46
- Coussens, 2002, Nature, 420, 860
- Campisi, 2007, Nature Rev Molec Cell Biol, 8, 729
- Dimri, 2005, Cancer Cell, 7, 505
- Ben-Porath, 2004, J Clin Invest, 113, 8
- Chau, 2003, Nature Rev Cancer, 3, 130
- Bargonetti, 2002, Curr Opin Oncol, 14, 86
- Braig, 2006, Cancer Res, 66, 2881
- Campisi, 2003, Nature Rev Canc, 3, 339
- Wright, 2001, Curr Opin Genet Dev, 11, 98
- Collins, 2003, Aging Cell, 2, 145
- Lowe, 2003, Curr Opin Genet Dev, 13, 77
- Ohtani, 2004, J Med Invest, 51, 146
- Gil, 2006, Nature Rev Molec Cell Biol, 7, 667
- Collado, 2005, Nature, 436, 642
- Chen, 2005, Nature, 436, 725
- Michaloglou, 2005, Nature, 436, 720
- Braig, 2005, Nature, 436, 660
- Shay, 2004, Oncogene, 23, 2919
- Ventura, 2007, Nature, 445, 661
- Xue, 2007, Nature, 445, 656
- Donehower, 2002, J Cell Physiol, 192, 23
- Faragher, 2000, Biochem Soc Trans, 28, 221
- Kortlever, 2006, Cell Cycle, 5, 2697
- Kirkwood, 2000, Nature, 408, 233
- Campisi, 2005, Cell, 120, 1
- Price, 2002, Aging Cell, 1, 57
- Vasile, 2001, FASEB J, 15, 458
- Matthews, 2006, Circ Res, 99, 156
- Maier, 2004, Genes Dev, 18, 306
- Tyner, 2002, Nature, 415, 45
- Zhang, 2003, Proc Natl Acad Sci U S A, 100, 3251
- Chang, 2002, Proc Natl Acad Sci U S A, 99, 389
- Bavik, 2006, Cancer Res, 66, 794
- Mason, 2004, Oncogene, 23, 9238
- Wajapeyee, 2008, Cell, 132, 363
- Kortlever, 2006, Nat Cell Biol, 8, 877
- Parrinello, 2005, J Cell Sci, 118, 485
- Kuilman, 2008, Cell, 133, 1019
- Acosta, 2008, Cell, 133, 1006
- Krtolica, 2001, Proc Natl Acad Sci U S A, 98, 12072
- Liu, 2007, Cancer Res, 67, 3117
- Parrinello, 2003, Nat Cell Biol, 5, 741
- Hayward, 1995, In Vitro Cell Dev Biol Anim, 31, 14
- Bello, 1997, Carcinogenesis, 18, 1215
- Kaighn, 1979, Invest Urol, 17, 16
- Chang, 1999, Oncogene, 18, 4808
- Schmitt, 2002, Cell, 109, 335
- Tannock, 2004, N Engl J Med, 351, 1502
- Cowin, 2005, Curr Opin Cell Biol, 17, 499
- Kokkinos, 2007, Cells Tissues Organs, 185, 191
- Dhawan, 2005, J Clin Invest, 115, 1765
- Yuan, 2005, Front Biosci, 10, 853
- Badache, 2001, Cancer Res, 61, 383
- Serrano, 1997, Cell, 88, 593
- Di Micco, 2006, Nature, 444, 638
- Mallette, 2007, Genes Dev, 21, 43
- Ancrile, 2007, Genes Dev, 21, 1714
- Yang, 2006, Proc Natl Acad Sci U S A, 103, 16472
- Akhurst, 2001, Trends Cell Biol, 11, 44
- Beausejour, 2003, EMBO J, 22, 4212
- Ossovskaya, 1996, Proc Natl Acad Sci U S A, 93, 10309
- Mantovani, 2006, Nature Rev Immunol, 6, 907
- Jeyapalan, 2007, Mech Ageing Dev, 128, 36
- Dimri, 1995, Proc Natl Acad Sci U S A, 92, 9363
- Paradis, 2001, Hum Pathol, 32, 327
- Melk, 2003, Kidney Int, 63, 2134
- Bruunsgaard, 2001, Curr Opin Hematol, 8, 131
- Williams, 1957, Evolution, 11, 398
- Roberts, 2006, Eur Spine J, 15, 312
- Herbig, 2006, Science, 311, 1257
- Bartkova, 2005, Nature, 434, 864
- Gorgoulis, 2005, Nature, 434, 907
- Kiaris, 2005, Cancer Res, 65, 1627
- Hill, 2005, Cell, 123, 1001
- Coppe, 2006, J Biol Chem, 281, 29568
- Kaminker, 2005, J Cell Sci, 118, 1321
- Kim, 2004, J Biol Chem, 279, 43799
- Krtolica, 2002, Cytometry, 49, 73
Cited by
Items 3,201–3,300 of 4,275
Limited Cell-Autonomous Anticancer Mechanisms in Long-Lived BatsPreprint
Athar, F., Zheng, Z., Riquier, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.29.582714 · Cited by 3
Lamming, D. W. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.00152-5 · Cited by 3
Cytokine-driven cancer immune evasion mechanisms
Arenas, E. J. (2025) · International review of cytology · doi:10.1016/bs.ircmb.2025.01.004 · Cited by 12
The paradigm of obstructive sleep apnea in aging: interactions with telomere length
Tempaku, P. F., & Tufik, S. (2018) · Sleep Medicine · doi:10.1016/j.sleep.2018.05.009 · Cited by 3
Cellular senescence and nanoparticle-based therapies: Current developments and perspectives
Henschke, A., Mielcarek, A., Grześkowiak, B. F., Perrigue, P. M., Jaskot, K., Coy, E. L., & Moya, S. E. (2024) · Nanotechnology Reviews · doi:10.1515/ntrev-2023-0211 · Cited by 6
Marizomib Promotes Senescence or Long-Term Apoptosis in Melanoma Cancer Cells
Piskorz, W. M., Krętowski, R., & Cechowska‐Pasko, M. (2024) · Molecules · doi:10.3390/molecules29235652 · Cited by 4
The cancer-associated secretory phenotype: a new frontier in targeted therapeutics
Tan, X., Xiao, G.-Y., Banerjee, P., Wang, S., & Kurie, J. M. (2024) · Journal of Clinical Investigation · doi:10.1172/jci182652 · Cited by 5
Liu, Y., & Chen, J. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1423725 · Cited by 4
Silva‐Álvarez, S. D., & Collado, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.00219-4 · Cited by 3
Pan, L., Shi, C., Choi, J., & Lin, J. (2025) · Cells · doi:10.3390/cells14201602 · Cited by 6
“This observation is consistent with the well-established concept that senescent cells acquire a senescence-associated secretory phenotype (SASP), characterized by the release of pro-inflammatory cytokines such as IL-6 [38,39].”
Carracedo, J., Bodega, G., Ramírez, R., & Alique, M. (2020) · Revista de Investigación y Educación en Ciencias de la Salud (RIECS) · doi:10.37536/riecs.2020.5.1.200 · Cited by 7
“En general, las células senescentes se caracterizan por tener un fenotipo secretor, liberando altos niveles de citoquinas pro-inflamatorias, mediadores inmunes, factores de crecimiento y proteasas [21, 23], entre otras sustancias (Tabla I).”
BackgroundSwan, M. (2010) · Symmetry · doi:10.3390/sym2010150 · Cited by 3
Patel, S. K., Bruderer, R., Basisty, N., Bons, J., Desprez, P., Neri, F., Reiter, L., Campisi, J., & Schilling, B. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.27.433188 · Cited by 4
Self-citationSadiq, A., & Fert‐Bober, J. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117579 · Cited by 3
Monyatovsky, H., Anderson, T., & Nadeau, J. (2025) · ACS Omega · doi:10.1021/acsomega.5c07583 · Cited by 3
SPP1 Regulates SASP via the p53 Signaling Pathway to Affect ALI Progression
Yuan, C., Zhao, S., Ma, W., Na, H., Tan, Q., & Gao, J. (2025) · IUBMB Life · doi:10.1002/iub.70038 · Cited by 5
Targeting persister cells: proactively overcoming therapy resistance in aggressive B cell lymphomas
Tao, J., Qiu, K., & Williams, M. E. (2026) · Trends in cancer · doi:10.1016/j.trecan.2025.12.007 · Cited by 3
Therapeutic Opportunities Presented by Modulation of Cellular Senescence
Faragher, R., Heidari, N., & Ostler, E. L. (2023) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-21410-3_8 · Cited by 3
Silva‐Álvarez, S. D., & Collado, M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-394447-4.30066-9 · Cited by 5
Regulatory Roles for SIRT1 in Aging and Immunosenescence
Brissett-Lasalle, D., Syed, Z., Yarubandi, Y., Leips, J., & Green, E. M. (2025) · Results and problems in cell differentiation · doi:10.1007/978-3-031-91459-1_10 · Cited by 4
[The effect of deep branches of cervical nerve on motorial function of trapezius muscle].
Wang, F., Wen, Y., & Li, L. (2003) · 华西口腔医学杂志 · Cited by 4
Cellular senescence and chronic inflammation
Ohtani, N. (2014) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.37.390 · Cited by 3
Aging-Associated Nonmelanoma Skin Cancer: A Role for the Dermis
Lewis, D. A., Krbanjevic, A., Travers, J. B., & Spandau, D. F. (2015) · Springer eBooks · doi:10.1007/978-3-642-27814-3_58-2 · Cited by 3
Integration of the DNA Damage Response with Innate Immune Pathways
Gordon, M., & Gasser, S. (2011) · InTech eBooks · doi:10.5772/24735 · Cited by 3
Goyer, M., Désaulniers-Langevin, C., Sonn, A., Nehmo, G. M., Lisi, V., Benabdallah, B., Raynal, N. J. ‐., & Beausejour, C. M. (2024) · Cells · doi:10.3390/cells13100849 · Cited by 6
Evolution and development of innate immune memory
Divangahi, M., & Kaufmann, E. (2026) · Science Immunology · doi:10.1126/sciimmunol.aeb7976 · Cited by 7
Natural killer cell-based senotherapy: a promising strategy for healthy aging
中澤務, Yamanishi, R., Morimoto, T., & Matusda, R. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1737572 · Cited by 4
Gabuardi, T. L., Lee, H. G., & Lee, K. J. (2022) · Scientific Reports · doi:10.1038/s41598-022-07865-2 · Cited by 4
Searching for Clinically Relevant Biomarkers in Geriatric Oncology
Κάτσιλα, Θ., Patrinos, G. P., & Kardamakis, D. M. (2018) · BioMed Research International · doi:10.1155/2018/3793154 · Cited by 4
“Senescence-associated secretory alterations G-SCF, IL-6, IL-8, GRO (a, b, g), IL-7, ICAM-1 [21, 32, 34, 35]”
Rai, P., & Troen, B. R. (2011) · Springer eBooks · doi:10.1007/978-1-4419-6999-6_2 · Cited by 3
Wang, D., Xie, D., Meng, S. Q., Mi, J., Wang, H., Li, L., Zhang, Y., & Cui, Y. (2024) · BMC Cancer · doi:10.1186/s12885-024-12957-5 · Cited by 5
“These factors are of senescence-associated secretory phenotype (SASP) [57].”
Background(2019) · doi:10.1101/2019.12.19.882225 · Cited by 81
“Activated oncogenes cause DNA strand breaks and induce DDR signaling, thereby promoting cellular senescence similar to cells exposed to DNA-damaging agents (Acosta et al, 2008; Coppe et al, 2008; Kuilman et al, 2008).”
BackgroundThe caloric restriction fallacy, rodent diet aids and the tumor suppression theory of agingPreprint
Wolf, A. M. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/a2689 · Cited by 2
Chui, M. K. K., Schneider, K., Miclau, K. R., LaHue, S. C., Furman, D., Leutwyler, H. C., & Newman, J. C. (2024) · medRxiv · doi:10.1101/2024.03.06.24303857 · Cited by 5
“SASP is comprised of cytokines and signaling molecules secreted by senescent cells, cells with various forms of damage that enter a state of permanent cell cycle arrest and accumulate with age 25 .”
BackgroundEarly growth response 2 (EGR2) is a novel regulator of the senescence program
(2020) · doi:10.1101/2020.09.30.321190 · Cited by 3
“In fibroblasts, it is further characterised by additional markers of senescence, most notably the senescence-associated secretory phenotype (SASP) (Coppé et al., 2008; Rodier et al., 2009), accompanied by elevated reactive oxygen species (ROS) levels (Passos et al., 2010; Lowe et al., 2015), and a loss of lamin B1 (Fr…”
BackgroundInfluentialAlexander, E. T., Barone, K. S., & Gilmour, S. K. (2025) · Molecular Carcinogenesis · doi:10.1002/mc.70034 · Cited by 4
Impact of senescence on the transdifferentiation process of human hepatic progenitor-like cells
Bellanti, F., di Bello, G., Tamborra, R., Amatruda, M., Buglio, A. L., Dobrakowski, M., Kasperczyk, A., Kasperczyk, S., Serviddio, G., & Vendemiale, G. (2021) · World Journal of Stem Cells · doi:10.4252/wjsc.v13.i10.1595 · Cited by 4
Aging Skin as a Diagnostic Tool for Internal Diseases: A Chance for Dermatology
Nikolakis, G. D., Makrantonaki, E., & Zouboulis, C. C. (2016) · Springer eBooks · doi:10.1007/978-3-662-47398-6_125 · Cited by 4
Mahmoudi, S., Mancini, E., Moore, A. L., Xu, L., Jahanbani, F., Hebestreit, K., Srinivasan, R., Li, X., Devarajan, K., Prélot, L., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/448431 · Cited by 3
Wang, F., Hui, S. T. Y., Stappenbeck, F., Kamińska, D., Lusis, A. J., & Parhami, F. (2025) · Cells · doi:10.3390/cells14151191 · Cited by 4
“In addition to irreversible cell cycle withdrawal, senescent cells typically exhibit common characteristics in morphology and SASP [45].”
Limitations of the p16-3MR mouse model for detecting and eliminating senescent cells
Hori, N., Kawamoto, S., Uemura, K., Kinugasa‐Katayama, Y., Okumura, Y., Tanaka, K., Park, J. H., Wakita, M., Motooka, D., Ohtani, N., et al. (2026) · EMBO Reports · doi:10.1038/s44319-026-00802-8 · Cited by 3
“Importantly, senescent cells acquire a characteristic known as the senescence-associated secretory phenotype (SASP), which involves the secretion of numerous pro-in fl ammatory factors (Acosta et al, 2008; Coppe et al, 2008; Kuilman et al, 2008).”
Rose, J., Schurman, C. A., King, C. D., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.20.517228 · Cited by 3
Martin, G. M. (2009) · The Journals of Gerontology Series A · doi:10.1093/gerona/glp053 · Cited by 3
In Vivo Skin Regeneration and Wound Healing Using Cell Micro-Transplantation
Nanić, L., Cedilak, A., Vidaček, N. Š., Грубер, Ф., Huzak, M., Bäder, M., & Rubelj, I. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091955 · Cited by 3
“An important aspect of SASP is the evolutionarily conserved expression profile of many factors between rodents (mice) and humans [17,18], which makes them a good experimental model relevant to humans.”
BackgroundAging Skin as a Diagnostic Tool for Internal Diseases: A Chance for Dermatology
Nikolakis, G. D., Makrantonaki, E., & Zouboulis, C. C. (2015) · Springer eBooks · doi:10.1007/978-3-642-27814-3_125-1 · Cited by 3
“Senescent cells are believed to force the surrounding cells in acquiring the so-called senescent-associated secretory phenotype by the secretion of various pro-inflammatory factors [38].”
BackgroundCiotlos, S., Wimer, L. A., Campisi, J., & Melov, S. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.17.529001 · Cited by 4
“SnCs acquire a SASP, which consists of chemokines, cytokines, growth factors, and matrix remodeling proteins [22-24].”
BackgroundSelf-citationShirasaka, R., Katagiri, T., & Futami, K. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150824 · Cited by 3
Immunosenescence - the sunset over the immune system
Chovancová, Z. (2020) · Vnitřní lékařství · doi:10.36290/vnl.2020.101 · Cited by 3
Huang, Y., Qiu, Z., Jiang, C., Fang, Q., Wang, J., Han, M., Liu, Y., & Li, Z. (2025) · Scientific Reports · doi:10.1038/s41598-025-00950-2 · Cited by 4
“Senescent cells may be one of the sources of chronic systemic inflammation: the senescence-associated secretory phenotype (SASP) is a group of proinflammatory cytokines, chemokines, and proteases secreted by senescent cells 9,24,25 , which collectively modify the local environment.”
Sidler, C. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803309-8.00029-x · Cited by 5
Carbón, A. M. T., Ojalvo, A. G., Fernández‐Montequín, J. I., Savigne-Gutiérrez, W., de Armas-López, G., Carbonell-López, C., Montero-Alvarez, S., Casillas, D., Pino-Fernández, G., & Berlanga‐Acosta, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178745 · Cited by 4
“Interestingly, the conditioned medium from these “diseased cells” is able to transmit and impose the above-mentioned abnormal traits to normal cultured fibroblasts [177].”
Palangat, M., Anastasakis, D. G., Liang, F., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/371492 · Cited by 3
Reconstructing the Molecular Life History of Gliomas
(2017) · doi:10.1101/192369 · Cited by 3
Brito‐de‐Sousa, J. P., Lima-Silva, M. L., da Costa-Rocha, I. A., Campi‐Azevedo, A. C., Mambrini, J. V. D. M., Faria, A. M. C., Lima‐Costa, M. F., Peixoto, S. V., Teixeira‐Carvalho, A., Torres, K., et al. (2025) · Experimental Gerontology · doi:10.1016/j.exger.2025.112700 · Cited by 3
Futami, K., Ito, H., & Katagiri, T. (2024) · Fish Physiology and Biochemistry · doi:10.1007/s10695-024-01423-5 · Cited by 3
“It has also been reported that p53 represses the induction of expression of SASP factors (Coppé et al. 2008).”
Cellular senescence: A novel mechanism of therapeutic resistance in prostate cancer
Lin, C., Hadfield, M. J., Rathore, A., Pinho-Schwermann, M. P., Zhang, S., Lu, S., den Hollander, P., Mani, S. A., Seyhan, A. A., Santopietro, A., et al. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103061 · Cited by 5
Instructive power of senescence
Bernard, D. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0042-x · Cited by 3
Elevated Senescence Markers in Developing Trisomy 21 Human Lungs
Belgacemi, R., Cherry, C. L., Thompson, M., Ngassie, M. L. K., Rehan, A., El-Alam, I., Saux, C. J. L., Glass, I. A., Britt, R. D., Prakash, Y. S., et al. (2025) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2024-0361oc · Cited by 6
Interplay of autophagy, apoptosis, and senescence in primary biliary cholangitis
Kouroumalis, E., Tsomidis, I., & Voumvouraki, A. (2023) · Exploration of Digestive Diseases · doi:10.37349/edd.2023.00028 · Cited by 3
Senescent cancer cells in immune surveillance and evasion: mechanisms and therapeutic implications
De-chang, L., Wang, J., Wei, Y., Wu, H. Y., Yuan, S., Yang, M. J., & Sun, L. (2025) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiaf125 · Cited by 5
Wu, R. T. Y., & Cheng, W. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-418680-4.00021-x · Cited by 4
Characterizing the SASP ‐Dependent Paracrine Spreading of Senescence Between Human Brain Cell Types
Russo, T., & Rießland, M. (2026) · Aging Cell · doi:10.1111/acel.70673 · Cited by 4
The existence of senescent cells in conjunctival epithelium from elderly individuals
Tomioka, Y., Kitazawa, K., Numa, K., Hughes, J. B., Yokoi, N., & Sotozono, C. (2024) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-023-01047-x · Cited by 3
Nie, A.-Y., Xiao, Z.-H., Deng, J., Li, N., Hao, L., Li, S.-H., & Hu, X.-Y. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i2.98556 · Cited by 3
Bronchud, M. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1982-5 · Cited by 3
Kitakaze, M., Chijimatsu, R., Vecchione, A. M., Kitagawa, T., Doki, Y., Eguchi, H., & Ishii, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147544 · Cited by 3
“As the common mechanism, if not all, the involvement of cancer promoting RAS oncogene, as well as tumor suppressor functions, such as TP53 or p16INK4a, has been proposed [38].”
BackgroundChilosi, M., Piciucchi, S., Ravaglia, C., Spagnolo, P., Sverzellati, N., Tomassetti, S., Wuyts, W. A., & Poletti, V. E. (2024) · Pulmonology · doi:10.1016/j.pulmoe.2024.05.005 · Cited by 6
Levin, M., & Adams, D. S. (2016) · Institute of Physics eBooks · doi:10.1088/978-0-7503-1326-1ch5 · Cited by 3
Advancing Single-Cell Detection of Senescent Cells: Laboratory Methods and Clinical Applications
Lung, S. H., & Lung, T. (2025) · OBM Geriatrics · doi:10.21926/obm.geriatr.2502307 · Cited by 4
HCV spontaneous clearers showed low senescence profile in people living with HIV under long ART
Lara‐Aguilar, V., Crespo‐Bermejo, C., Llamas-Adán, M., Grande‐García, S., Cortijo‐Alfonso, M. E., Martín‐Carbonero, L., Domínguez, L., Ryan, P., Santos, I. D. L., Bartolomé‐Sanchez, S., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28955 · Cited by 3
An Update on the Molecular Pillars of Aging
García‐Velázquez, L., & Arias, C. (2020) · Springer eBooks · doi:10.1007/978-3-030-40955-5_1 · Cited by 6
Mining Cellular Senescence for Drug Targets
Bilsland, A. E., & Keith, W. N. (2009) · Springer eBooks · doi:10.1007/978-1-4419-1075-2_10 · Cited by 3
“Finally, senescent cells express a complex secretory phenotype including expression of several growth factors and inflammatory cytokines including IL-6, IL-8 and FGF-7 (Coppe et al. 2008).”
BackgroundInfluentialRajesh, A., Havas, A. P., Arnold, R., Lande, K., Lei, X., Li, K. Y., Gandhi, A., Franco, A. C., Woo, S., Lagnado, A. B., et al. (2026) · Nature Aging · doi:10.1038/s43587-026-01196-x · Cited by 10
Gomez, L. S., & Jurk, D. (2024) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-66768-8_5 · Cited by 4
Olinger, B., Anerillas, C., Herman, A. B., Tsitsipatis, D., Banarjee, R., Tanaka, T., Candia, J., Maragkakis, M., Bandinelli, S., Walker, K. A., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117389 · Cited by 4
“3 These senescence-associated proteins (SAPs) have since proven to be heterogeneous by cell type and senescence-inducing stimulus.”
Multiple outcomes of the germline p16INK4a mutation affecting senescence and immunity in human skin
Subramanian, P., Sayegh, S., Laphanuwat, P., Devine, O., Fantecelle, C. H., Sikora, J., Chambers, E. S., Karagiannis, S. N., Gomes, D. C. O., Kulkarni, A. A., et al. (2024) · Aging Cell · doi:10.1111/acel.14373 · Cited by 4
“…en - compasses the secretion of soluble pro-inflammatory cytokines, chemokines, growth factors, angiogenic factors and matrix metal - loproteinases (Coppé et al., 2008 ). p16 INK4a has a role in SASP se - cretion, with loss of p16 INK4a in oncogene-induced senescent human fibroblasts and melanoma…”
Premalignant lesions and cellular senescence
Georgakopoulou, E. A., Evangelou, K., & Gorgoulis, V. G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822514-1.00001-8 · Cited by 4
Klinaki, E., & Ogrodnik, M. B. (2024) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2024.111929 · Cited by 3
A single nuclei atlas of aging human abdominal subcutaneous white adipose tissuePreprint
Sparks, L. M., Whytock, K. L., Divoux, A., Sun, Y., Pino, M., Yu, G., Smith, S. R., & Walsh, M. J. (2023) · Research Square · doi:10.21203/rs.3.rs-3097605/v1 · Cited by 3
Self-citationOpportunities and Challenges of Targeting an Aging Immune System
Roesel, M. J., Matsunaga, T., & Tullius, S. G. (2021) · Transplantation · doi:10.1097/tp.0000000000003930 · Cited by 3
Photon and particle radiotherapy induce redundant modular chemotaxis of human lymphocytes
Kraske, J. A., Allers, M. M., Smirnov, A., Lenoir, B., Ahmed, A., Suarez‐Carmona, M., Hampel, M., Krunic, D., Tietz-Dalfuß, A., Beikert, T., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.190149 · Cited by 5
Choi, M., Lee, D., Yang, W.-H., & Cha, J. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08688-z · Cited by 4
“Similarly, in prostate cancer, SASP components such as MMPs, IL-6, CXCL1, and CXCL8 contribute to the establishment of a pro-metastatic niche by promoting ECM degradation and modulating immune cell in fi ltration [16, 96, 97].”
Targeting Senescent Cells to Improve Human Health
Wijshake, T., & van Deursen, J. M. A. (2016) · Healthy ageing and longevity · doi:10.1007/978-3-319-26239-0_16 · Cited by 3
“ATM and checkpoint kinase 2 (CHK2) and is a slow and gradual process (Coppé et al. 2008; Rodier et al. 2009).”
BackgroundInfluentialMishra, K., Puthli, A., & Tiwari, R. (2016) · Journal of Radiation and Cancer Research · doi:10.4103/jrcr.jrcr_7_17 · Cited by 3
Shimoyama, Y., Yamada, K., Yoshida, S., Kawamura, A., Hannya, Y., Imaizumi, Y., Kumamoto, T., Takeda, Y., Shimoda, M., Eto, K., et al. (2023) · Cancer Science · doi:10.1111/cas.15768 · Cited by 4
(2021) · doi:10.1101/2021.05.03.442497 · Cited by 99
“The SASP has been shown to play a role in paracrine signaling whereby senescent cells can promote local wound healing and/or drive healthy neighboring cells into senescence (Acosta et al., 2013; Coppé et al., 2006; Demaria et al., 2014; Coppé et al., 2008).”
BackgroundGupta, Y., & Welford, S. M. (2016) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789813147324_0005 · Cited by 2
Zhou, S., Jian, L., Chen, H., Yin, H., Ji, F., Yang, M., & Wu, H. (2026) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-026-09164-4 · Cited by 2
“2) [27, 118].”
The Changing Face of Atherosclerosis
Meiliana, A., & Wijaya, A. (2023) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v15i3.2347 · Cited by 3
The role of senescence in cancer therapy-associated cardiovascular toxicity
Alshoubaki, Y. K., Grüterich, V., Zollet, V., & Kuster, G. M. (2024) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2024.14 · Cited by 2
Non-Canonical Senescence Phenotype in Resistance to CDK4/6 Inhibitors in ER-Positive Breast Cancer
Mammadova, A., Gu, Y., Ruan, L., Badve, S., & Gökmen‐Polar, Y. (2026) · Biomolecules · doi:10.3390/biom16010093 · Cited by 3
“The term SASP was first described by Campisi’s group highlighting the complex secretory profile of senescent cells [14].”
Progress of immune senescence in multiple myeloma treatment resistance
Jia, Y., Yan, L., Fan, C., Sun, H., Zhou, X., & Shi, Z. (2025) · Discover Oncology · doi:10.1007/s12672-025-02136-8 · Cited by 5
Angiopoietin-like 8 governs osteoblast-adipocyte lineage commitment during skeletal aging
Guo, Y., Zhang, Z., He, J., Luo, P., Wang, Z., Zhu, Y., Meng, X., Pan, L., Kan, R., Xiang, Y., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.189371 · Cited by 5
Platelet Immune Interactions, Lifespan, and Senescence
Nydegger, U. E., & Imbach, P. A. (2025) · OBM Geriatrics · doi:10.21926/obm.geriatr.2501297 · Cited by 2
Li, T., Zhang, Y., Zhou, X., Ji, S., Zhou, Z., Wang, W., Shen, L., Liu, H., Xie, Z., & Ruan, Y. (2026) · Environment International · doi:10.1016/j.envint.2026.110085 · Cited by 4
Metadata
- Authors
- Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J.
- Affiliations
- Lawrence Berkeley National Laboratory (US)
- Fred Hutch Cancer Center (US)
- Buck Institute for Research on Aging (US)
- Corresponding author
- Campisi, Judith
- Venue
- PLoS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 6
- Issue
- 12
- Pages
- e301
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- PMC
- PMC2592359
- OpenAlex
- W239602587
- Cited by
- 302
- References
- 81
- Citations by year
- 2025: 16 · 2024: 29 · 2023: 30 · 2022: 38 · 2021: 49 · 2020: 26 · 2019: 15 · 2018: 12 · 2017: 16 · 2016: 16 · 2015: 11 · 2014: 8 · 2013: 4 · 2012: 9
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of North Texas Digital Library (University of North Texas) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Lawrence Berkeley National Laboratory
- Funders
- Larry L. Hillblom Foundation
- University of Washington
- National Institutes of Health (AG09909, AG017242, CA126540, AG000266)
- National Institute on Aging (R56AG009909, AG017242, AG-09909, R37AG009909, AG000266, P01AG017242, T32AG000266)
- National Cancer Institute (CA126540, CA 97186, U54CA126540, P50CA097186)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- senescence-associated secretory phenotype, cellular senescence, genotoxic stress, oncogenic Ras, p53 tumor suppressor, paracrine signaling, interleukin-6, interleukin-8, epithelial-mesenchymal transition, tumor invasion, prostate cancer chemotherapy, tissue microenvironment, age-related cancer
- MeSH terms
- Adult, Aging, Antineoplastic Agents, Cells, Cultured, Epithelial Cells, Fibroblasts, Humans, Infant, Newborn, Male, Neoplasm Invasiveness, Neoplasms, Phenotype, Prostatic Neoplasms, Genes, ras, Interleukin-6, Tumor Suppressor Protein p53, Interleukin-8, Cellular Senescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.